Dear Editor, The molecular heterogeneity of AML underlies the wide variation in responses to standard therapy. This heterogeneity occurs at multiple regulatory steps affecting cell survival and proliferation (1) . We identified overexpression of the eukaryotic translation initiation factor 4E (eIF4E) as a targetable aberrancy in all examined cases of M4 and M5 FAB (French, American and British) AML subtypes, as well as in some M0, M1, and M2 subtypes (2) . eIF4E is both overexpressed and highly enriched in the nucleus of these specimens. eIF4E acts in nuclear mRNA export and translation of specific transcripts necessary for the promotion of proliferation, survival and metastases (3, 4) . These eIF4E functions depend on its binding the m 7 G cap on the 5' end of mRNAs (3, 4) . Use of ribavirin, a competitive inhibitor of the m 7 G cap, impairs the biochemical and oncogenic functions of eIF4E (5, 6) . The first clinical trial to directly target eIF4E activity used ribavirin in AML patients with elevated eIF4E who were unfit for induction chemotherapy or who had relapsed disease(7). Complete and partial responses were observed, and responding patients demonstrated a reduction in overall levels of eIF4E, loss of its nuclear localization and impaired production of eIF4E targets(7).
In vitro combination studies with ribavirin and cytarabine showed an added impairment in cell growth in primary AML patient samples(8). Given these findings, we combined ribavirin po BID continuous dosing with low dose cytarabine (LDAC) sc BID for 10 days every 28 days in a phase I trial following a "3+3 design" ( Table 1 ). The primary objective was to determine the recommended phase II dose (RP2D) of the combination based on pharmacokinetics and safety.
The secondary objectives revealed predicted cellular changes in eIF4E but also a novel mechanism of resistance to ribavirin and cytarabine(10). Twenty-nine patients with elevated eIF4E and who were unsuitable for induction chemotherapy or with relapsed/refractory disease were enrolled. Nine of these had not received induction with 7+3 for their AML (median age 70 years), and three received prior therapy for myelodysplastic syndrome (MDS) ( Table 2 ). The combination was generally well tolerated with no unexpected adverse events. Haemolytic anemia, a known ribavirin toxicity, was seen in 4 patients (14%), and was uncontrolled by dose reduction but resolved after ribavirin was discontinued.
In the first dose escalation, four dose levels of ribavirin (1000, 1400, 1800 and 2200 mg BID)
were combined with LDAC 20 mg BID. At a ribavirin dose of 2200 mg BID, there were 2 dose limiting toxicities (DLTs), and no further dose escalation was performed. Importantly, the mean maximum ribavirin plasma levels were below 20uM for all dose levels (Supplemental Figure 1 ).
This was in contrast to levels above 20uM seen with monotherapy, where patients were treated with ribavirin 1000 mg BID. Interestingly, patient 1 had a doubling of ribavirin serum levels once LDAC was reduced to 10 mg BID for toxicity during cycle 2 ( Figure 1 ). Thereafter, this patient achieved a CR (with incomplete red cell recovery), and molecular targeting of eIF4E, as seen by re-localization to the cytoplasm. This patient remained on ribavirin therapy for two years with LDAC discontinued on day 179.
Given the observation with patient 1 and the failure to achieve higher plasma levels of ribavirin in the higher dose cohorts, we carried out a second ribavirin dose escalation in the presence of LDAC 10 mg BID. This led to increased ribavirin plasma levels overall (Supplemental Figure 1) .
The median maximum level of ribavirin when given with LDAC 10 mg BID was 23uM (6-37, n=9), more than double that observed at LDAC 20 mg BID, which was 11.5uM (range=2-33, n=10). Increasing doses of ribavirin beyond 1400 mg BID did not result in increased serum steady state levels (Supplemental Figure 1) . No DLTs were observed in this dose escalation.
Thus, the recommended Phase II dose (RP2D) was determined to be ribavirin 1400 mg BID and LDAC 10 mg BID.
Twenty-one patients treated for 28 or more days were evaluable for response. There were 2
CRs, 1 partial remission, and 2 blast responses (Table 1) . Responding patients had a median ribavirin plasma level of 33uM at best response whereas non-responders had a median maximum ribavirin plasma level of 19uM. In total, 14 patients had a maximum plasma level of ribavirin >20uM, and all 5 responding patients were in this group. The addition of LDAC to ribavirin tended to increase the median time to treatment failure from 104 days for the monotherapy trial (range= 93-263 days, n=3) to 225 days (range= 96-743 days, n=3), although the number of patients included in both trials is small. Patients with adverse cytogenetics(9)
were less likely to respond. No difference in FLT3 ITD/mutation or NPM1 mutation among responders and non-responders was observed.
Clinical response correlated with molecular targeting of eIF4E. Targeting was determined by changes in eIF4E mRNA levels and eIF4E protein re-localization to the cytoplasm. Protein levels of eIF4E and its downstream targets were assessed when sufficient material was available. No targeting of eIF4E was observed among patients with PD. Six patients had a full molecular response with both lower eIF4E levels and eIF4E re-localization (Supplemental Table   1 ) including the patients who achieved CR, PR, BR (Table 1 ). All had 20+ uM maximum plasma levels of ribavirin. Patients 3 and 10 had a partial molecular response, whereby they did not have full relocalization of eIF4E. For patient 3, determination of ribavirin plasma levels was inaccurate because of frequent dose interruptions due to haemolytic anemia. Of the three patients (3, 10 and 22) with partial or full molecular response that did not achieve PR, CR or BR, all showed a decrease in blast count and/or hematologic improvement. Levels above 20 uM ribavirin were also observed in some non-responders, indicating that ribavirin level alone did not predict response. At relapse, all six patients with complete eIF4E targeting showed eIF4E relocalization back to the nucleus and elevated eIF4E levels consistent with the loss of clinical activity (Supplemental Table 1 ). Similarly, the partial molecular response was lost by patients 3 and 10 at progression.
In our previous monotherapy trial, we noted upon clinical relapse an increase in the levels of the sonic hedgehog transcription factor Gli1, which led to glucuronidation of ribavirin, loss of the eIF4E-ribavirin interaction, and ultimately drug resistance (10). Additionally, primary refractory and a few relapsed patients had markers of impaired drug uptake with low levels of the ribavirin transporter (ENT1) and/or an enzyme required for the pro-drug metabolism of ribavirin, adenosine kinase (ADK)(10). We examined these resistance markers here (Supplemental Table   1 ). For 5/27 patients, we observed lowered ADK and/or ENT1 mRNA and/or protein levels at baseline relative to healthy volunteers, suggesting that ribavirin pro-drug metabolism and drug uptake were impaired. None of these 5 patients responded to treatment. An additional 3/18 and 6/18 patients had reduced ADK or ENT1 levels at relapse/EOT relative to before treatment, respectively. For 14/18 patients, we observed an elevation in Gli1 and/or UDPglucunosyltransferase 1A (UGT1A) at the end of treatment, relative to before treatment. In our resistance studies, elevated Gli1 correlated with increased UGT1A protein levels, ribavirin and cytarabine glucuronidation and drug resistance(10). Finally, as in our monotherapy trial, many non-responding patients had elevated Gli1 or low ADK/ENT1 levels underlying their primary resistance. Thus, these patients likely did not respond due to inactive drug. Some patients had markers of both Gli1/UGT1A and ADK/ENT1 mediated resistance.
In summary, we identified the RP2D of ribavirin and LDAC,1400 mg po BID continuous dosing and 10 mg sc BID for 10 days of a 28 day cycle respectively. This combination is well tolerated, with some patients achieving marked clinical responses. Our results indicate that ribavirin plasma levels are reduced in the presence of LDAC, which impairs the absorption of ribavirin, as was shown with other drugs(11). In addition, LDAC may interfere with ribavirin activity, as patients in the prior monotherapy trial responded molecularly and clinically to ribavirin at lower serum levels(7). Nonetheless, once higher levels of ribavirin were achieved the combination with LDAC may have yielded longer time on study compared with ribavirin alone for patients who achieved remission. A phase II study is needed to determine the rate and duration of response for this combination. Importantly, cellular changes in eIF4E required plasma levels of ribavirin above 20uM in the presence of LDAC, supporting our clinical observation that this level is associated with response.
Tracking eIF4E targeting, ENT1, ADK, Gli1, UGT1A as well as ribavirin and cytarabine uptake likely predict response and relapse respectively. We will test the efficacy of overcoming Gli1 inducible drug glucuronidation in an AML trial combining a Gli1 inhibitor with ribavirin (NCT02073838). The development of additional drug combinations is also important. Our previous ex vivo AML studies suggest that combinations of eIF4E with azacytidine could be useful (8). Further, augmenting the inhibitory effects of ribavirin on eIF4E using Mnk kinase inhibitors or rapalogues could be effective. In summary, our second clinical trial targeting eIF4E
with ribavirin led to clinical responses and highlighted the importance of monitoring resistance markers in AML.
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Supplemental Figure 1 . Cohorts of patients were treated with incrementing doses of ribavirin and two different doses of LDAC, see Table 1 . Venous blood samples were collected from patients prior to start of treatment (C1D1), 24 hours (C1D2), 15 days, and 28 days (C2D1) post-start of treatment. Mean plasma levels are represented and error bars indicate standard deviations. Plasma levels of ribavirin were measured by Apredica Pharmaceutical (Watertown, MA, USA) using LC-MS methods.
Supplemental Materials and methods

Patient Selection
Patients with a diagnosis of either de novo, secondary AML after myelodysplastic or myeloproliferative disorder, therapy related AML of M4 or M5 French-American-British FAB subtypes subtype or high eIF4E, were eligible to participate in this study. Patients must also have been at least 18 years of age; and must have had an Eastern Cooperative Oncology Group (ECOG) performance status lower than 3; a life expectancy of at least 12 weeks; adequate hepatic and renal function (hepatic transaminase level lower than 2.5 times the institutional upper limit of normal ULN, total bilirubin level less than 1. ClinicalTrials.gov registry is NCT01056523.
Treatment regimen
Cytarabine was administered subcutaneously at a fixed dose of 20 mg twice a day from days 1 to day 10. Due to absorption issues, cytarabine was reduced to 10 mg twice a day from days 1 to day 10. Ribavirin (originally purchased from Zydus Pharmaceuticals, Pennington, NJ, USA and then subsequently donated by Pharmascience Inc., Montreal, Quebec, Canada) was administered continuously, twice daily with food at escalating doses.
Evaluation of response
To assess response to therapy, a bone marrow aspirate was performed prior to study start and at the end of every 28 day cycle. Clinical responses were assessed using the Cheson criteria(1). A complete remission (CR) was defined as absence of leukemic blasts from peripheral blood, fewer than 5% blasts in bone marrow, peripheral level of hemoglobin higher than 90 g/L (higher than 9 g/dL), platelet count greater than 100 × 109/L and absolute neutrophil count greater than 1 × 10 9 /L. A designation of complete remission with incomplete blood count recovery (CRi) required that all criteria for a CR were met, but that there was either a residual neutropenia (<1 × 10 9 /L) or thrombocytopenia (<100 × 10 9 /L). Partial remission (PR) required the hematologic criteria for CR, and a 50% reduction in bone marrow blasts with a post-treatment blast count between 5 and 25%.
Incomplete partial remission (PRi) required the same marrow criteria as PR but allowed for an incomplete recovery or neutrophils and platelets as for CRi. A blast response (BR) required a greater than 2-log decrease in absolute peripheral blood blast count and/or at least a 50% decrease in bone marrow blast percentage sustained for a 28-day period in the absence of fulfilling the criteria for a CR, CRi, PR, or PRi. Progressive disease (PD) was defined as a 50% increase in the absolute number of blasts in the bone marrow relative to baseline, or an increase in the absolute peripheral blast count of at least 10 × 10 9 /L. Stable disease (SD) was defined as failure to achieve a BR, yet not fulfilling the criteria for PD. The best response for each patient was recorded.
Study design
Ribavirin dose levels were escalated following the "3+3 design" in order to determine the maximum tolerated dose (MTD). Cohorts of 3 patients were treated with incrementing doses of ribavirin, see Table 1 The plasma was transferred into sterile, polypropylene cryovials and stored at -70°C.
Plasma levels of ribavirin were measured by Apredica Pharmaceuticals (Watertown, MA, USA) using LC-MS methods. Whenever possible, specimens were divided into 2 or 3 samples and ribavirin levels analyzed in duplicate or triplicate. Pure ribavirin (Kemoprotec, Middlesborough, United Kingdom) was used as a standard. In no instance was ribavirin observed in the samples obtained prior to the start of treatment. LDAC levels were not deteremined because it is the same molecular weight as cytosine, confounding measurement efforts.
Correlative studies
Primary AML specimens and healthy volunteers: Patients were analyzed for eIF4E, ENT1, ADK, Gli1 and UGT1A mRNA and protein (whenever possible) levels. Leukemic blasts were isolated using side and forward scatter as described in (2) . Briefly, white blood cells were isolated from peripheral blood or bone marrow using Ficoll Gradient.
Leukemic blasts were then isolated using CD45 dim side-scatter population as was Protein and RNA were isolated as described (2) . Screening of FLT3 ITDs and TDKs as well as NPM1 mutations were done from RNAs by RT-PCR using primers previously described (2, 5, 6) .
Reverse transcription andQuantitative PCR: DNAse treated RNA samples (TurboDNase, Ambion) were reverse transcribed using Supervilo kit (Invitrogen) for primary specimens. QPCR analyses were performed using EXPRESS SYBR® GreenER™ QPCR SuperMix (Invitrogen) in AB StepOne thermal cycler using the relative standard curve method (Applied Biosystems User Bulletin #2). All conditions were described previously(2,3).
Primers list includes:
Gli1Fw(GGCTGCAGTAAAGCCTTCAGCAAT), 
Western Blot Analysis:
Western analysis was performed as described previously(2,3).
Immunofluorescence and laser-scanning confocal microscopy: Immunostaining was n/a n/a n/a n/a n/a 3. SD 0.6 +/-no change no change no change 4. PD no change no change no change no change 0.46 5. SD n/a no change n/a (BT levels 4x higher than Normal controls) n/a n/a (BT levels 2x lower than Normal controls) 6. BR 0.7 + x3.5 no change 0.5 7. PD no change no change no change (BT levels 3x higher than Normal controls) no change no change 8. SD 0.4 no change x1.8 no change no change 9. PD n/a n/a n/a n/a n/a 10. SD 0.5 +/-x1.5 no change 0.3 11. N/A n/a n/a n/a (BT levels 7.5x higher than Normal samples) n/a (lower protein levels BT than Normal samples) n/a 12. SD no change +/-x2 no change no change 14. PD no change no change x6 no change no change 15. N/A n/a n/a n/a (BT levels 5x higher than Normal samples) n/a (BT levels 2x lower than Normal controls) n/a 16. PR 0.3 + no change no change no change 17. N/A n/a n/a n/a (Levels 3x higher than Normal samples at EOT) n/a n/a 18. PD n/a no change n/a (BT levels 6x higher than Normal samples) n/a (BT levels 2x lower than Normal controls) n/a n/a n/a (High Gli1 protein levels) n/a n/a 28. SD n/a no change n/a (BT levels 3x higher than Normal samples) n/a n/a recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org.
